2976-0526
2976-0526
S2976-05262025000100036
10.71749/pkj.89
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
Portugal
00
03
2025
00
03
2025
39
1
36
43
[
O'Keeffe AG.Su L.Urowitz MB.Romero-Diaz J.Gordon C
2016
55
252-62
]
[
2017
33
17-25
]
[
2022
62
200-8
]
[
2025
64
1201-9
]
[
Kidney Disease: Improving Global Outcomes Lupus Nephritis Work Group
2024
105
S1-S69
]
[
2024
83
15-29
]
[
2005
8
140-74
]
[
2020
7
316
]
[
]
[
2011
377
721-31
]
[
2011
63
3918-30
]
[
2018
77
]
[
2017
69
1016-27
]
[
2018
70
1256-64
]
[
D'Cruz D.Maksimowicz -McKinnon K.Oates J.Santiago MB.Bass D.Burriss S
2019
6
A149-50
]
[
2017
69
115-23
]
[
2018
48
467-74
]
[
2020
383
1117-28
]
[
Dall'Era M.Cisternas MG.Smilek DE.Straub L.Houssiau FA.Cervera R
2015
67
1305-13
]
[
2023
38
2733-42
]
[
2022
101
403-13
]
[
2022
17
1620-30
]
[
2022
9
975-91
]
[
2023
9
218-28
]
[
2023
32
1394-401
]
[
2021
124
102729
]
[
Infarmed
]
[
van der Velde M.Astor BC.Woodward M.Levey AS
2011
80
93-104
]
[
2019
14
469-81
]
[
2009
20
1103-12
]
[
Dall'Era M.Stone D.Levesque V.Cisternas M.Wofsy D
2011
63
351-7
]
[
D'Cruz D.Sebastiani GD.de Ramon Garrido E.Danieli MG
2004
50
3934-40
]
[
FDA
]
[
2014
64
821-35
]
[
Inês LS et al
2021
60
5134-41
]
[
2022
11
5017
]